More than 10 years’ research has gone into developing the once-daily, 125ml drink. The formula contains a patented combination of nutrients that supports the normal metabolic pathways involved in the formation of new synapses in the brain.
Loss of synapses, which provide the functional connections in the brain, is one of the key elements of Alzheimer’s disease, particularly in the early stages.
Souvenaid addresses this nutritional shortfall and has been shown in clinical trials to improve episodic memory in people with early Alzheimer’s disease.
The trials indicated that drinking Souvenaid once a day over 24 weeks improved the memory performance of people in the early stages of Alzheimer’s disease, as measured by functional tests of memory compared with the placebo group.
Available in two flavours, vanilla and strawberry.
© FoodBev Media Ltd 2024